4.5 Review

The Related Metabolic Diseases and Treatments of Obesity

期刊

HEALTHCARE
卷 10, 期 9, 页码 -

出版社

MDPI
DOI: 10.3390/healthcare10091616

关键词

obesity; comorbidities; molecular signaling pathways; treatment; drugs; clinical trials

向作者/读者索取更多资源

Obesity is a chronic disease affecting over 1 billion people worldwide, characterized by abnormal accumulation of body fat and commonly associated with other metabolic disorders. Factors such as sedentary lifestyle, overnutrition, genetic and environmental conditions contribute to the development of obesity. Various strategies for obesity management and treatment include exercise, dietary changes, surgery, and medications. Psychological management plays a significant role, especially for distressed patients. Gut microbiota has a crucial role in obesity and its associated conditions, and microbial reprogramming through methods like fecal microbiota transplantation shows promise. Prevention and early treatment of obesity are essential in preventing its progression to comorbidities.
Obesity is a chronic disease characterized by the abnormal or excessive accumulation of body fat, affecting more than 1 billion people worldwide. Obesity is commonly associated with other metabolic disorders, such as type 2 diabetes, non-alcoholic fatty liver disease, cardiovascular diseases, chronic kidney disease, and cancers. Factors such as a sedentary lifestyle, overnutrition, socioeconomic status, and other environmental and genetic conditions can cause obesity. Many molecules and signaling pathways are involved in the pathogenesis of obesity, such as nuclear factor (NF)-kappa B, Toll-like receptors (TLRs), adhesion molecules, G protein-coupled receptors (GPCRs), programmed cell death 1 (PD-1)/programmed death-ligand 1 (PD-L1), and sirtuin 1 (SIRT1). Commonly used strategies of obesity management and treatment include exercise and dietary change or restriction for the early stage of obesity, bariatric surgery for server obesity, and Food and Drug Administration (FDA)-approved medicines such as semaglutide and liraglutide that can be used as monotherapy or as a synergistic treatment. In addition, psychological management, especially for patients with obesity and distress, is a good option. Gut microbiota plays an important role in obesity and its comorbidities, and gut microbial reprogramming by fecal microbiota transplantation (FMT), probiotics, prebiotics, or synbiotics shows promising potential in obesity and metabolic syndrome. Many clinical trials are ongoing to evaluate the therapeutic effects of different treatments. Currently, prevention and early treatment of obesity are the best options to prevent its progression to many comorbidities.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据